Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | LTK | P29376 | 1/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980399 | 0.88 | CDK8 (0.65) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL162420 | 0.88 | CDK8 (0.65) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL10855370 | 0.84 | HDAC1 (0.49) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL11070341 | 0.84 | CDC7 (0.53) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL844056 | 0.83 | BCL2L1 (0.58) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL2009820 | 0.82 | DYRK1A (0.56) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL21470630 | 0.81 | DYRK1A (0.49) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL2176222 | 0.81 | HDAC1 (0.52) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL10857362 | 0.81 | HDAC1 (0.60) | CDK8GSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL2012989 | 0.80 | HDAC1 (0.54) | CDK8GSK3AGSK3BDYRK1AAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-4577014-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4501739-A | BACTERICIDES, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CDK8 3350/4885GSK3A 3626/4885GSK3B 3189/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | CDK8 1828/4885GSK3A 2897/4885GSK3B 2231/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | CDK8 1570/4885GSK3A 728/4885GSK3B 837/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | CDK8 1324/4885GSK3A 677/4885GSK3B 578/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CDK8 1540/4885GSK3A 609/4885GSK3B 527/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | CDK8 443/4885GSK3A 843/4885GSK3B 686/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CDK8 1580/4885GSK3A 1286/4885GSK3B 1154/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | CDK8 2388/4885GSK3A 1051/4885GSK3B 909/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CDK8 1580/4885GSK3A 1286/4885GSK3B 1154/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | CDK8 2388/4885GSK3A 1051/4885GSK3B 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.